Literature DB >> 19483733

Genetics: Predictive value of KRAS mutations in chemoresistant CRC.

Astrid Lièvre1, Pierre Laurent-Puig.   

Abstract

On the basis of the results of KRAS analysis from the CO.17 randomized, controlled, phase III study by Karapetis et al., KRAS mutations have emerged as a valid predictive marker associated with resistance to cetuximab and lack of survival benefit from this anti-EGFR antibody in patients with chemoresistant colorectal cancer.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19483733     DOI： 10.1038/nrclinonc.2009.69

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  9 in total

1.  KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

Authors:  W De Roock; H Piessevaux; J De Schutter; M Janssens; G De Hertogh; N Personeni; B Biesmans; J-L Van Laethem; M Peeters; Y Humblet; E Van Cutsem; S Tejpar
Journal:  Ann Oncol       Date:  2007-11-12       Impact factor: 32.976

2.  K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.

Authors:  Marie-Christine Etienne-Grimaldi; Jean-Louis Formento; Mireille Francoual; Eric François; Patricia Formento; Nicole Renée; Pierre Laurent-Puig; Maurice Chazal; Daniel Benchimol; Jean-Robert Delpero; Christian Letoublon; Denis Pezet; Jean-François Seitz; Gérard Milano
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

3.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

Authors:  David Cunningham; Yves Humblet; Salvatore Siena; David Khayat; Harry Bleiberg; Armando Santoro; Danny Bets; Matthias Mueser; Andreas Harstrick; Chris Verslype; Ian Chau; Eric Van Cutsem
Journal:  N Engl J Med       Date:  2004-07-22       Impact factor: 91.245

4.  Cetuximab for the treatment of colorectal cancer.

Authors:  Derek J Jonker; Chris J O'Callaghan; Christos S Karapetis; John R Zalcberg; Dongsheng Tu; Heather-Jane Au; Scott R Berry; Marianne Krahn; Timothy Price; R John Simes; Niall C Tebbutt; Guy van Hazel; Rafal Wierzbicki; Christiane Langer; Malcolm J Moore
Journal:  N Engl J Med       Date:  2007-11-15       Impact factor: 91.245

5.  Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

Authors:  Leonard B Saltz; Neal J Meropol; Patrick J Loehrer; Michael N Needle; Justin Kopit; Robert J Mayer
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

6.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Authors:  Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

7.  Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

Authors:  Carsten Bokemeyer; Igor Bondarenko; Anatoly Makhson; Joerg T Hartmann; Jorge Aparicio; Filippo de Braud; Serban Donea; Heinz Ludwig; Gunter Schuch; Christopher Stroh; Anja H Loos; Angela Zubel; Piotr Koralewski
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

8.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors:  Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544

9.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Authors:  Federica Di Nicolantonio; Miriam Martini; Francesca Molinari; Andrea Sartore-Bianchi; Sabrina Arena; Piercarlo Saletti; Sara De Dosso; Luca Mazzucchelli; Milo Frattini; Salvatore Siena; Alberto Bardelli
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544
  9 in total
  13 in total

1.  PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.

Authors:  Arjun Sood; Danielle McClain; Radhashree Maitra; Atrayee Basu-Mallick; Raviraja Seetharam; Andreas Kaubisch; Lakshmi Rajdev; John M Mariadason; Kathryn Tanaka; Sanjay Goel
Journal:  Clin Colorectal Cancer       Date:  2012-01-28       Impact factor: 4.481

2.  Translational biomarkers: from preclinical to clinical a report of 2009 AAPS/ACCP Biomarker Workshop.

Authors:  Jane P F Bai; Robert Bell; ShaAvhree Buckman; Gilbert J Burckart; Hans-Georg Eichler; Kenneth C Fang; Federico M Goodsaid; William J Jusko; Lawrence L Lesko; Bernd Meibohm; Scott D Patterson; Oscar Puig; Jeffrey B Smerage; Barbara J Snider; John A Wagner; Jingsong Wang; Marc K Walton; Russell Weiner
Journal:  AAPS J       Date:  2011-03-30       Impact factor: 4.009

3.  Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.

Authors:  Julio Garcia-Aguilar; Zhenbin Chen; David D Smith; Wenyan Li; Robert D Madoff; Peter Cataldo; Jorge Marcet; Carlos Pastor
Journal:  Ann Surg       Date:  2011-09       Impact factor: 12.969

4.  Global mutational profiling of formalin-fixed human colon cancers from a pathology archive.

Authors:  Mark D Adams; Martina L Veigl; Zhenghe Wang; Neil Molyneux; Shuying Sun; Kishore Guda; Xiaoqing Yu; Sanford D Markowitz; Joseph Willis
Journal:  Mod Pathol       Date:  2012-08-10       Impact factor: 7.842

5.  Establishment of genetically diverse patient-derived xenografts of colorectal cancer.

Authors:  Danielle M Burgenske; David J Monsma; Dawna Dylewski; Stephanie B Scott; Aaron D Sayfie; Donald G Kim; Martin Luchtefeld; Katie R Martin; Paul Stephenson; Galen Hostetter; Nadav Dujovny; Jeffrey P MacKeigan
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

6.  Activation of ERK signaling and induction of colon cancer cell death by piperlongumine.

Authors:  H Randhawa; K Kibble; H Zeng; M P Moyer; K M Reindl
Journal:  Toxicol In Vitro       Date:  2013-04-18       Impact factor: 3.500

7.  The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial.

Authors:  Arnaud Pagès; Stéphanie Foulon; Zhaomin Zou; Ludovic Lacroix; François Lemare; Thierry de Baère; Christophe Massard; Jean-Charles Soria; Julia Bonastre
Journal:  Genet Med       Date:  2016-12-01       Impact factor: 8.822

8.  Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery.

Authors:  Olfa Derbel; Qing Wang; Françoise Desseigne; Michel Rivoire; Pierre Meeus; Patrice Peyrat; Mattia Stella; Isabelle Martel-Lafay; Anne-Isabelle Lemaistre; Christelle de La Fouchardière
Journal:  BMC Cancer       Date:  2013-04-23       Impact factor: 4.430

9.  Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review.

Authors:  Amartej Merla; Sanjay Goel
Journal:  Chemother Res Pract       Date:  2012-10-14

10.  Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique.

Authors:  Mark Kriegsmann; Norbert Arens; Volker Endris; Wilko Weichert; Jörg Kriegsmann
Journal:  Diagn Pathol       Date:  2015-07-30       Impact factor: 2.644
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.